Food Technology Magazine | Issues and Insights
Digesting the Impact of Anti-Obesity Drugs
Food companies may be able to satisfy the needs of the growing cohort of GLP-1 medication users while also targeting a generally health-conscious population.
© KuznetsovDmitry/istock/getty images plus
The use of anti-obesity medications (AOMs), led by glucagon-like peptide-1 (GLP-1) agonists like Ozempic (semaglutide), has skyrocketed over the past few years. These powerful drugs, prescribed for both type 2 diabetes and weight loss, work by mimicking a unique gut hormone that suppresses appetite and slows how fast the stomach empties after eating.
Unsurprisingly, as the number of people prescribed these medications continues to grow, eating and purchasing behaviors are changing. In a recent s…
